Nuformix plc (LON:NFX – Get Free Report) shares dropped 18% during trading on Friday . The stock traded as low as GBX 0.08 ($0.00) and last traded at GBX 0.08 ($0.00). Approximately 10,914,796 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 76,368,313 shares. The stock had previously closed at GBX 0.10 ($0.00).
Nuformix Trading Down 14.0 %
The firm has a 50-day moving average of GBX 0.06 and a 200 day moving average of GBX 0.09. The stock has a market capitalization of £1.06 million, a price-to-earnings ratio of -2.61 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- How to Most Effectively Use the MarketBeat Earnings Screener
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- How to trade using analyst ratings
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- What is the Australian Securities Exchange (ASX)
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
